APL 400-003

BIOLOGICAL4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Wyeth-Lederle Vaccines, Apollon

Conditions

Acquired Immunodeficiency SyndromeHIV InfectionHIV InfectionsHIV Seronegativity

Phase 1

Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers

CompletedNCT00002231

Wyeth-Lederle VaccinesHIV Infections, HIV Seronegativity

Updated: 2005-06-24

A Study of GENEVAX-HIV, a Possible Vaccine

CompletedNCT00002232

Wyeth-Lederle VaccinesHIV Infections, HIV Seronegativity

Updated: 2005-06-24

A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients

CompletedNCT00002350

ApollonHIV Infections

Target: 16Updated: 2005-06-24

Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers

CompletedNCT00001538

National Institute of Allergy and Infectious Diseases (NIAID)Acquired Immunodeficiency Syndrome, HIV Infection

Start: 1996-03-31End: 2001-04-30Target: 41Updated: 2008-03-04